Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Article Details
- CitationCopy to clipboard
Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Cancer Invest. 2008 Oct;26(8):794-9. doi: 10.1080/07357900802087242.
- PubMed ID
- 18798063 [ View in PubMed]
- Abstract
TAS-102 is a novel formulation of the fluorinated pyrimidine analogue trifluorothymidine (FTD) with an inhibitor of thymidine phosphorylase. The purpose of this study was to determine the MTD and DLT for TAS-102 administered three times a day on days 1-5 and 8-12 every 4 weeks. Fifteen patients were enrolled with two patients experiencing dose-limiting fatigue and granulocytopenia at the first dose level (80 mg/m2/day). Granulocytopenia was the primary toxicity: 7 patients experienced grade 3 or 4 granulocytopenia with the first course. No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Trifluridine DNA Nucleotide Humans YesOther/unknownDetails Trifluridine Thymidylate synthase Protein Humans YesInhibitorDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Trifluridine Thymidine phosphorylase Protein Humans UnknownSubstrateDetails